Lilly diabetes exec joins AmideBio as CEO

17 May 2018

AmideBio, a privately held US biotech company, has announced that Dr Pawel Fludzinski has joined the company as its new chief executive.

With his extensive background developing drugs targeting diabetes at Eli Lilly (NYSE: LLY), Dr Fludzinski was selected as the ideal candidate to lead AmideBio's development of its drug candidates targeting metabolic diseases. Dr Misha Plam, who has served as CEO since the company's inception in 2009, will continue as president and chairman.

"I am honored and excited to become the CEO at AmideBio," said Dr Fludzinski, adding: "AmideBio's novel approach to developing glucose responsive insulins (GRI) promises to radically improve diabetes treatment. I look forward to leading the GRI effort as well as other growth opportunities."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK